Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 9110974Search this ID in NIH RePORTER
- ScienceDex PI coverage
- FY2025 through FY2026Career claims are limited to the years shown.
NIH Funding · FY2025
Linked Award Amount
$625K
Full award amounts, FY2025
Award Records
2
Records listing this PI
Award-Linked Rank
#26,577
By linked amount among FY2025 PIs
Earliest Year Loaded
2025
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2025 award records by amount
NIH award records listing Daniel J. Moore as a PI. Multi-PI records show the full award amount for context.
- 5R01DK137997-02R01Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes$339.1Kaward amount
- 5R01DK139322-02R01Optimizing Stage 2 T1DM Management: Assessing the Impact of GLP-1Ra on Metabolic Outcomes in Patients Receiving Teplizumab$286Kaward amount
Award organization
Organizations that administered FY2025 awards listing Daniel J. Moore as a PI.
FY2025 award administered by Vanderbilt University Medical Center (TN).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2025First NIH AwardVanderbilt University Medical Center
- 2025$500K Cumulative Funding
- 2025R01 Grant Holder